KeyBanc Keeps Overweight on Castle Biosciences and Five9
KeyBanc maintained its Overweight rating on Five9 and raised its Castle Biosciences price target to $40 from $35, Dow Jones Newswires reported.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
KeyBanc maintained its Overweight rating on Castle Biosciences and raised its price target on the stock from $35 to $40. Dow Jones Newswires reported this, citing ratings data from Benzinga.
KeyBanc also kept its Overweight rating on Five9. The report contains no new price target for that company.
why it matters
Analyst decisions like these usually shape sentiment around individual stocks rather than the broader market. For investors, this is a routine event, mainly relevant to those following the two companies.
tags
instruments
sources
- Castle Biosciences Is Maintained at Overweight by Keybanc — Dow Jones Newswires, 6 November 2026 at 14:24 UTC
- Five9 Is Maintained at Overweight by Keybanc — Dow Jones Newswires, 6 November 2026 at 14:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗